Biotech
Sherlock Biosciences
Sherlock Biosciences raises $220M Series C at $1.5B valuation
$220M
Total Raised
Series C
Latest Round
2019
Founded
150+
Employees
201 Brookline Avenue, Boston, MA 02215
1 min read
Quick Facts
Valuation
$1.5B
Latest Round Size
$220M
Latest Round Date
January 2024
Sherlock Biosciences: Series C Funding Round
Sherlock Biosciences has successfully raised $220M in Series C funding, reaching a valuation of $1.5B.
Company Overview
CRISPR-powered diagnostics
Funding Details
The Series C round was led by Vivo Capital, with participation from Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation.
Company Information
- Headquarters: 201 Brookline Avenue, Boston, MA 02215
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Sherlock Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Vivo Capital: Verified investor in Series C
- Baillie Gifford: Verified investor in Series C
- GV: Verified investor in Series C
- Taiho Ventures: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
- William K. Warren Foundation: Verified investor in Series C
Key Investors
Vivo Capital
Lead Investor
Verified investor in Series C
Baillie Gifford
Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
Taiho Ventures
Investor
Verified investor in Series C
Perceptive Advisors
Investor
Verified investor in Series C
William K. Warren Foundation
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M